Figures
Abstract
Objective
To use multilevel functional principal component analysis to exploit the information inherent in the shape of longitudinally sampled glucose curves during pregnancy, and to analyse the impact of glucose curve characteristics on neonatal birth weight, percentage fat and cord blood C-peptide.
Study Design and Setting
A cohort study of healthy, pregnant women (n = 884). They underwent two oral glucose tolerance tests (gestational weeks 14–16 and 30–32), which gave two glucose curves per woman.
Results
Glucose values were higher, and peaked later in third trimester than in early pregnancy. The curve characteristic “general glucose level” accounted for 91% of the variation across visits, and 72% within visits. The curve characteristics “timing of postprandial peak”, and “oscillating glucose levels” accounted for a larger part of the variation within visits (15% and 8%), than across visits (7% and <2%). A late postprandial peak during pregnancy, and high general glucose levels in third trimester had significant, positive effects on birth weight (p<0.05). Generally high glucose levels during pregnancy had a significant, positive impact on neonatal percentage fat (p = 0.04). High general glucose level in third trimester had a significant, positive impact on cord blood C-peptide (p = 0.004).
Citation: Frøslie KF, Røislien J, Qvigstad E, Godang K, Bollerslev J, Henriksen T, et al. (2014) Shape Information in Repeated Glucose Curves during Pregnancy Provided Significant Physiological Information for Neonatal Outcomes. PLoS ONE 9(3): e90798. https://doi.org/10.1371/journal.pone.0090798
Editor: Marià Alemany, University of Barcelona, Faculty of Biology, Spain
Received: October 18, 2013; Accepted: February 5, 2014; Published: March 11, 2014
Copyright: © 2014 Frøslie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for the study was provided by the Norwegian Health Association; Faculty of Medicine, University of Oslo; Department of Obstetrics and Gynaecology and the National Resource Centre for Women's Health, Oslo University Hospital Rikshospitalet. Roche Diagnostics, Norway supplied glucometers and test strips free of charge. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
High maternal glucose levels in pregnancy have adverse short-term and long-term health effects for both the mother and the child [1]–[5]. The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study investigated glucose intolerance less severe than that in overt diabetes mellitus, and demonstrated effects on the risk of adverse pregnancy outcomes [1]: Positive, linear effects were found for the fasting, one-hour (1-h) and two-hour (2-h) values from oral glucose tolerance tests (OGTTs). Other studies reporting associations between high maternal glucose levels and adverse pregnancy outcomes have used a variety of simple glucose measures, e.g. the fasting value, the 2-h value, area under the curve (AUC), impaired fasting glucose, gestational diabetes (GDM) diagnosis or HbA1c [6]–[12].
Changes in glucose metabolism during pregnancy include increasing insulin resistance and increasing gluconeogenesis in the liver [13]. Counterintuitive to this, longitudinal studies have reported a decrease in fasting glucose levels during pregnancy, particularly during the first trimester [13]–[15]. However, concomitantly with the decrease in fasting glucose, elevated postprandial levels during pregnancy have been reported [9], [16], [17]. Some studies have described glucose curves or glucose data at different gestational ages and longitudinal changes in these curves and data during pregnancy [9], [16], [18], [19]. Few studies have analysed the impact of information in the shape of entire OGTT glucose curves [20], and except from one study [16],we are not aware of statistical analysis of longitudinal change in glucose curves during pregnancy. Also, few have studied the impact of change in glucose levels during pregnancy on neonatal outcomes [21], [22].
Functional data analysis (FDA) is a collection of statistical methods developed to analyse curve data [23], [24]. In FDA a set of temporal observations is treated as a single, functional object. The statistical analysis is based on this continuous function (curve), rather than on the original discrete data points. Information from the curve as a whole is extracted.
In a previous article [20], we used FDA to extract curve shape information from glucose curves from OGTT at one time point in pregnancy (gestational weeks 14–16), and compared it with the information from commonly used simple summary measures. We found that FDA extracted physiologically interpretable and clinically interesting characteristics of the glucose response, which was not identified by simple summary measures, and would otherwise be missed [20]. In particular, the curve shape characteristic “time to peak”, discriminated between women with and without gestational diabetes later in pregnancy, while the simple summary measures (including AUC) did not. Based on these findings, we now extend the analysis to study the shape inherent in glucose curves from two visits during pregnancy. The aim is to extract physiologically interpretable curve shape characteristics from longitudinally sampled glucose curves during pregnancy, and to incorporate such information in explanatory models. To our knowledge, this is the first study to use all information in longitudinally collected glucose curves, and to analyse the effect of such information on neonatal outcomes.
The STORK study, a Norwegian prospective cohort study of 1031 healthy, pregnant women, provided OGTT data from gestational weeks 14–16 and 30–32 [25]. Using FDA methodology developed by Di et al [26] and Crainiceanu and Goldsmith [27], we performed a multilevel FDA of the OGTT data, and extracted essential characteristics of the OGTT glucose curves from gestational weeks 14–16 and 30–32. We then studied the effect of these characteristics on the neonatal outcomes birth weight, percentage fat and C-peptide in cord blood.
Methods
Ethics Statement
The study was approved by the Regional Committee for Medical Research Ethics, Southern Norway, Oslo, Norway (reference number S-01191), and performed according to the Declaration of Helsinki. All participating women provided written informed consent.
Participants and data
The STORK study is a prospective cohort of 1031 healthy, Norwegian women of Scandinavian heritage who registered for obstetric care at Oslo University Hospital Rikshospitalet from 2001 to 2008. The overall aim of the study was to extend insights into maternal metabolic syndrome and determinants of foetal macrosomia [28]. Exclusion criteria were multiple pregnancies, known pre-gestational diabetes, and severe chronic diseases (pulmonary, cardiac, gastrointestinal or renal). Gestational age at inclusion was based on the Naegele's rule, and gestational ages at the other visits and at birth were based on routine ultrasound at weeks 17–19. Age, parity, smoking habits, height, weight, fasting insulin and a 75 g OGTT were recorded at inclusion at weeks 14–16. Weight, fasting insulin and OGTT were also recorded at weeks 30–32.
Blood samples were drawn in the morning, between 0730 and 0830 after an overnight fast, and were obtained from veni-puncture in tubes containing Ethylenediaminetetraacetic acid (EDTA). Plasma glucose was measured immediately in a drop of fresh, whole EDTA blood. During the OGTT, blood samples were taken every 30 minute for 2 hours. Glucose measurements were done by the Accu-Chek Sensor (ACS) glucometer (Roche Diagnostics GmbH, Mannheim, Germany). Due to an unexpected increasing trend in the fasting glucose measurements over the 7 years of recruitment, all glucose measurements were de-trended prior to the analyses [29]. The mean yearly increase in the original fasting glucose values was 0.11 mmol/l, 95% CI (0.09, 0.12) mmol/l. After the de-trending, the mean yearly increase was 0.01 mmol/l (−0.003, 0.024) mmol/l. The umbilical cord blood was collected into EDTA tubes by the midwife, centrifuged for plasma separation and placed at −20°C for less than a month and stored long term at −80°C.
Women with premature births or non-complete OGTT data were excluded, giving a study sample of 884 women and their neonates (Figure 1).
Birth weight was recorded within two hours after the birth. In a subsample of the cohort, the percentage of neonatal body fat was measured by Dual-energy X-ray absorptiometry (DXA) scanning, and C-peptide in cord blood from the time of birth was measured (Figure 1) [30], [31].
Data description
Descriptive statistics of registered data are presented as mean, standard deviation (SD) and range, or frequency and percentage (%).
Fitting continuous and individually smoothed curves
The OGTT measurements from the two visits were converted into 884 continuous, smooth OGTT glucose curves (hereafter called glucose curves), from gestational weeks 14–16, and 884 continuous, smooth glucose curves from gestational weeks 30–32. The curve fitting procedure was based on B-splines basis functions and is described in Appendix S1.
The functional multilevel model
When functional data like glucose curves are observed on two or more occasions for each individual, we apply a multilevel model for functional data to extract information [26], [27], as described below. See Appendix S1 for details.
Assume that the individual, true blood glucose curve for woman
at visit
in the continuous time span from 0 to 120 minutes,
, can be decomposed into fixed and random effects curves (Figure 2A), and expressed as a multilevel model of functional data
(1)Here the fixed effects curves are the overall mean glucose curve
(Figure 2Ai), and the mean visit-specific deviation from the overall mean curve,
(Figure 2Aii). Together, these terms constitute the visit-specific mean curve,
(Figure 2Cii). The random effects curves are
, the subject-specific deviation from the visit-specific mean curve (Figure 2Aiii), and
, the subject- and visit-specific deviation from the subject-specific mean curve (Figure 2Aiv).
In all plots in the figure, the horizontal axis is time during the 2−2 to 12.5 mmol/l. The horizontal, grey line is 0 mmol/l. is the glucose curve from 0 to 120 min for woman
at visit
;
is the overall mean glucose curve;
is the visit-specific deviation from the overall mean curve;
is the subject-specific deviation from the visit-specific mean curve; and
is the subject- and visit-specific deviation from the subject-specific mean curve.
Extracting common temporal characteristics: functional principal component (FPC) curves
An important task in FDA is to quantify the common characteristics of a set of curves. The common characteristics of the curves ,
and of the curves
,
and
in expression (1) (Figure 2Aiii and 2Aiv) are found by functional principal component analysis (FPCA). FPCA extracts FPC curves that describe characteristics associated with the largest proportions of the variation in the curves. See Appendix S1 for details. The FPC curves estimated in the multilevel FPCA may be interpreted and labelled according to the physiological information they exhibit.
Estimating FPC scores
In order to quantify each individual glucose curve's characteristics, we estimate individual scores for each FPC curve. A woman's FPC scores reflect how her individual curve trajectories at the two visits correspond to the common characteristics expressed by the FPC curves. Then we can study how glucose curve characteristics vary from woman to woman, and from visit to visit.
A woman's scores for the FPC curves of quantify her subject-specific deviation from the visit-specific mean curve, i.e. the important characteristics of her glucose curves across visits (Figure 2Biii and 2Ciii). Her scores for the FPC curves of
quantify her subject- and visit-specific deviation from her subject-specific mean curve, i.e. the characteristics of the residual variation within a visit (Figure 2Biv and 2Civ).
By combining equation (1) with the FPC curves and corresponding estimated FPC scores, an individual glucose curve can be expressed as the sum of the visit-specific mean, , and a linear combination of a small number of the FPC curves for
and
(Equation (3) in Appendix S1) [26], [27].
FPC curves are often illustrated by plots showing how an individual curve differs from the mean curve if the FPC scores are high or low, rather than plots of the FPC curves directly.
Correlation between FPC scores and traditional AUC
The traditional, simple summary measure AUC was calculated directly from the de-trended glucose measurements by the trapezoid method. Pearson's correlation coefficients (r) were used to compare AUC with FPC scores.
Functional information in regression analyses
The impact of glucose curve characteristics on the neonatal outcomes birth weight, percentage fat and C-peptide in cord blood were estimated using linear regression with FPC scores from the multilevel FPCA as explanatory variables. The interpretation of the effect estimates is based on the physiological interpretation of the FPC scores. Adjusted effect estimates were found by multiple linear regression analyses with most FPC scores (the first subject- and visit-specific score at gestational weeks 14–16 was left out due to colinearity issues), early pregnancy BMI, age and parity as explanatory variables. The multivariable analyses involved stepwise variable selection procedures based on Akaike's information criterion (AIC), analyses of several models considered to be of importance, and considerations of physiological importance of the findings. Model diagnostics were thoroughly checked during the analysis. The final multiple models presented in the results section include only the variables identified by these procedures.
In supplementary analyses, we repeated the analyses of birth weight for the reduced samples where percentage fat and C-peptide were available.
Software
All analyses were performed in R 3.0.0. The estimation of FPC scores was done by the R2WinBUGS package that runs WinBUGS from R [32]. The technical details are given in Appendix S1, and the implementation is given in the program code, which is available in Appendix S2.
Results
Data description
Characteristics of the study sample at inclusion at gestational weeks 14–16, at gestational weeks 30–32 and at birth are shown in Table 1. Except from a significantly lower proportion of smokers in the study sample (p = 0.01), no significant differences were found between the women and the neonates in the study sample, and those who were excluded (0.41≤p≤1.00). There was a small increase in fasting glucose and a large increase in fasting insulin from inclusion to weeks 30–32. The 2-h glucose levels were elevated in third trimester, and the prevalence of GDM increased from 0.3% at inclusion to 6% in third trimester.
Fitted curves
The smoothed glucose curves at gestational weeks 14–16 (Figure 3A) and 30–32 (Figure 3B) showed large variations between the women at both visits. Glucose values were higher, and it took longer time for postprandial glucose levels to get back to fasting levels at gestational weeks 30–32 than at weeks 14–16.
Plots A and B show individually smoothed curves from gestational weeks 14–16 and 30–32 (black lines) and the visit-specific mean curves (grey lines). Plots C and D show the overall mean of the fitted curves (grey lines) and how the shape of an individual curve differs from the overall mean if a multiplum of the subject-specific FPC curves is added to (+) or subtracted from (−) the mean curve. Plots E–G and H–J show the visit-specific means at gestational weeks 14–16 and 30–32, respectively (grey lines), and how the shape of an individual curve differs from the visit-specific mean if a multiplum of the subject- and visit-specific FPC curves is added to (+) or subtracted from (−) this mean. The multiplums correspond to 2 SDs of the corresponding FPC scores.
Common temporal characteristics: FPC curves and FPC scores
In the multilevel FPCA, the first two subject-specific FPCs explained 98% of the variation across visits, and the first three subject- and visit-specific FPCs explained 92% of the residual variation within visits. Further analyses were restricted to these FPC curves and the corresponding FPC scores (FPC1subj and FPC2subj, and FPC114–16, FPC214–16, FPC314–16, FPC130–32, FPC230–32 and FPC330–32, respectively). The FPC1 and FPC2 curves had very similar temporal appearances across and within visits.
Figure 3C–J show how individual curves differ from the overall and visit-specific mean curves if the FPCsubj, FPC14–16 and FPC30–32 scores are high or low. The dominating curve characteristic for the variation across visits, FPC1subj, accounting for 91% of this variation, was given the interpretation “general glucose level”. Women with high FPC1subj scores had glucose curves above the overall mean, and a somewhat later postprandial peak, whereas women with low FPC1subj scores had glucose curves below the overall mean (Figure 3C).
The second most important curve characteristic across visits (FPC2subj) was “timing of postprandial peak”. Women with low FPC2subj scores had a clear early peak and low glucose values at the end of the OGTTs (Figure 3D). Women with high FPC2subj scores had a later postprandial peak and high glucose values at the end of the OGTTs. This was seen in plots of individual curves from women with the lowest and highest FPC2subj scores (plots not shown).
The dominating curve characteristic for the residual variation within visits (accounting for 72% of this variation), was “general glucose level within visits”, i.e. the general glucose level not accounted for by the general glucose level across visits. A woman with a high subject- and visit-specific FPC114–16 (FPC130–32) score had a glucose curve above the subject-specific mean at weeks 14–16 (30–32) (Figure 3E and 3H). An example of this is the upper curve in Figure 2Biv and 2Civ. Similarly, a woman with a low FPC114–16 (FPC130–32) score had a glucose curve below the subject-specific mean at weeks 14–16 (30–32). An example of this is the lower curve in Figure 2Biv and 2Civ.
The second most important curve characteristic for the variation within visits was “timing of postprandial peak within visits”. A woman with a low FPC214–16 (FPC230–32) score had a clear early peak, and low glucose values at the end of this OGTT (Figure 3F and 3I). A woman with a high FPC214–16 (FPC230–32) score at weeks 14–16 (30–32) had a later postprandial peak, with high glucose values at the end of this OGTT (plots of individual curves not shown).
The third most important curve characteristic for the variation within visits was “oscillating glucose within visits”. The glucose curves of women with high FPC314–16 or FPC330–32 scores had two postprandial peaks during the corresponding OGTT, whereas women with low FPC314–16 or FPC330–32 scores had only one glucose peak during the OGTT (Figure 3G and 3J). The characteristics “peak” and “oscillations” accounted for a smaller part of the variation across visits (7% and less than 2%), than within visits (15% and 8%).
Figure 4 exemplifies the relation between individual glucose curves and corresponding FPC scores. The cyan, blue and black curves are glucose curves from three women in the study with curves above the mean (grey curve) at both visits. Consequently, the FPC1subj scores were high. The women with the green, red and purple curves had low FPC1subj scores. The woman with cyan curves and generally high glucose levels on both OGTTs, had a curve that was high above the mean at gestational weeks 14–16, but less so at gestational weeks 30–32. Thus, her FPC114–16 score was high, and her FPC130–32 score low.
The upper, left plot shows the individual glucose curves from 6 women at gestational weeks 14–16, and the upper, right plot shows the glucose curves from the same 6 women at gestational weeks 30–32. The lower plot shows the FPC scores for the same 6 women. The grey curves in the upper plots are the mean glucose curves at gestational weeks 14–16 (left) and 30–32 (right). Correspondingly, the grey line in the lower plot is zero.
There were strong correlations between FPC1subj scores and AUC at weeks 14–16 and weeks 30–32 (r = 0.86 and 0.90, respectively), between FPC114–16 and AUC14–16 (r = 0.73), and between FPC130–32 and AUC30–32 (r = 0.87). All correlations are given in Table S1. All FPC1 scores were positively correlated with BMI (0.12≤r≤0.35).
Regression analyses
Crude analyses showed significant positive effects on the three neonatal outcomes of the general glucose level across visits (FPC1subj), and of the subject- and visit-specific general glucose level at weeks 30–32 (FPC130–32) (Table 2). There was also a significant effect of a subject-specific late peak (FPC2subj) on birth weight.
In multivariable analyses of birth weight, only FPC2suband FPC130–32 scores remained significant (Table 2): Women with late postprandial peaks (low FPC2subj scores) would be expected to have babies with higher birth weight than women with early postprandial peaks (high FPC2subj scores), and women with the highest residual glucose levels in third trimester (high FPC130–32 scores) would be expected to have babies with higher birth weight than women with low residual glucose levels in third trimester (low FPC130–32 scores).
In multivariable analyses of neonatal percentage of fat, the effect of the FPC1subj scores remained significant (Table 2): Women with generally high glucose levels during their OGTTs (high FPC1subj scores) would be expected to have babies with a higher percentage of fat than women with generally low glucose levels during their OGTTs (low FPC1subj scores). According to AIC, FPC2subj scores also held information important for this outcome, although not statistically significant in the final model: Low FPC2subj scores, implying late glucose peaks, corresponded with high values of neonatal percentage fat.
In multivariable analyses of C-peptide in cord blood, the effect of FPC130–32 scores remained significant (Table 2): Women with high FPC130–32 scores gave birth to babies with higher mean C-peptide than women with low FPC130–32 scores. According to AIC, FPC314–16 scores also held important information, although not statistically significant: The neonates of women with oscillating glucose curves (high FPC314–16 scores) had somewhat lower C-peptide levels than those with one glucose peak during the OGTT (low FPC314–16 scores).
Supplementary analyses showed that alternative models chosen due to physiological theories, and to explore the effects of colinearity, gave the same results for all three outcomes. Analyses of birth weight in reduced samples where percentage fat or C-peptide was available showed significant effects of FPC1subj in both subsamples, of FPC214–16 in the percentage fat subsample, and a non-significant contribution of FPC230–32 in the C-peptide subsample.
Discussion
The present study successfully used multilevel FDA to analyse changes in longitudinally observed glucose curves during pregnancy. The general glucose levels, in particular postprandial glucose, increased from early pregnancy to gestational weeks 30–32, and postprandial glucose peaked later in gestational weeks 30–32. The glucose characteristics extracted by FPCA had significant impact of glucose curve characteristics on birth weight, neonatal percentage of fat, and C-peptide in cord blood, demonstrating physiological relevance.
The physiological interpretation of FPC curves is essential for the usefulness of FPCA. The identification of the general glucose levels as the most dominant characteristics of individual glucose curves was supported by the strong associations between FPC1 scores and the AUCs. The elevated postprandial levels in third trimester, the small increase in fasting glucose, and the large increase in fasting insulin and prevalence of GDM from inclusion to weeks 30–32 (Table 1), are in accordance with an expected progressive insulin resistance among pregnant women [13]. This supports the finding of timing of postprandial peak as the second most important curve characteristic. The general glucose level accounted for a larger part of the variation across, than within visits, whereas the timing of the peak was more important for the variation within, than across visits. This is not surprising, as FPC2 represent more curvature than FPC1, and some of the curvature may be averaged out at the subject-specific level. The FPC3 curve was interpreted as “oscillating glucose within visits”, although the scarcely sampled glucose measurements at each OGTT could only reveal two glucose peaks. The term “oscillations” was chosen due to physiological theories [33], [34].
The regression results for birth weight in Table 2 were strengthened by the consistency of the results from alternative models. The different results for birth weight in the subsamples with percentage fat or cord blood C-peptide may be a consequence of colinearity issues in combination with the reduced sample size. Notably, in all these analyses, both a “general level” and a “timing of peak” characteristic were identified as important for birth weight.
The sample size in the present study was substantial, but the women were healthy and relatively homogenous. This may have caused less variation in the individual glucose curves and made it more difficult to extract important discriminating curve characteristics. Also, the scarce sampling of glucose during the OGTT is likely to obscure the extraction and interpretation of the curve characteristics. More physiologically interesting temporal details and better discriminating abilities of the FPCs may be expected in a more heterogeneous population, and from OGTT curves over more than 2 hours or with a more frequent OGTT sampling. With more measurements per OGTT, it is also possible to apply alternative smoothing strategies [27]. In this study, the smoothing involved both a roughness penalty when fitting individual curves, and leaving out the FPCs which explained the smallest part of the variation, i.e. those with the waviest appearance. This might have given a too conservative estimate of the amount of curvature in the individual curves, which again could have caused bias in the FPC scores and thereby affected the regression results. It is also possible that the methods of covariance matrix estimation did not perfectly separate the across and within variances, influencing the colinearity, and thereby the variable selection.
Compared to studies presenting intravenous glucose tolerance tests [35], the glucose measurements per woman per OGTT in our study were few. They were, nevertheless, samples from an underlying, continuous and temporal process, and this made FDA a natural choice of analysis [24]. Alternative analyses include ordinary principal component analysis (PCA) of the five glucose measurements, and using these PCA scores as input in the regression analyses instead of FPCA scores. With only five measurements per curve, and measurements taken at the same time points for each woman, this would be expected to extract similar information as the FDA. However, FDA emphasizes the basic assumption about continuity of the underlying process, provides interpretations of curve features in this context, and opens for analysis of the derivatives of the curves [24]. FDA is also easier to apply in situations with more frequent sampling, sampling at unequal time points, and missing data.
The finding of the general glucose level as the most important glucose curve characteristic is in accordance with the numerous studies focusing on elevated glucose of various types, e.g. fasting, 1-h, 2-h or HbA1c values, in diabetes research [1], [13], [36]. Also, the increase in postprandial values during pregnancy, and corresponding delay in postprandial peak, found in the present study, is supported by several earlier studies [9], [14], [16], [18], [37]. FPC1 scores were positively associated with BMI, indicating that higher BMI leads to generally higher glucose levels. This is also in accordance with physiological knowledge of obesity and insulin resistance [13], [38] and our recent findings [20]. Many studies have found a decline in fasting glucose during the first trimester of pregnancy [15], but an overview of longitudinal studies during pregnancy showed conflicting results concerning later pregnancy fasting glucose [15]. This justifies our findings of a small increase in fasting glucose from weeks 14–16, to 30–32. Hence, current knowledge of metabolic changes during pregnancy supports the interpretations of the FPCs as plausible and potentially important physiological characteristics.
The HAPO study is a reference study for the impact of maternal blood glucose levels on pregnancy outcomes, and has found statistically significant higher odds ratios for high birth weight, cord-blood serum C-peptide level and percentage body fat (above their respective 90th percentiles), for high fasting, 1-hour and 2-hour glucose levels [1], [39]. This supports our findings of important impact of FPC1 scores, interpreted as “general glucose level”, on these outcomes. Other studies with a similar scope, but smaller sample sizes are also in accordance with these findings [2], [4], [6]–[8]. However, none of these studies addressed the impact of the dynamic regulation of the blood glucose, which is embedded in the FPC2 and FPC3 scores. Some studies have commented on the postprandial peak and birth outcomes [9], [22], [40], but to our knowledge, our previous study [20] is the only study that has formally investigated the impact of the timing of the postprandial peak.
We earlier found that for glucose curves from early pregnancy, the AUC was strongly correlated with FPC scores that provided information about the general glucose level during the OGTT, but not with scores providing information about timing of postprandial peak or oscillations, nor with the fasting or 2-h values [20]. This was also found in the present study (Table S1). Our recommendation is therefore to use AUC values rather than the fasting values or 2-h values, if FDA is not applied.
An important application of FDA techniques concerns research and clinical settings where continuous glucose monitoring devices are used [41]. Currently, many such studies restrict the analyses to simple summary measures like the mean glucose [17], [42], resulting in loss of potentially important information, as demonstrated in [20]. With the increased use of continuous glucose monitoring, there is a strong need for methods that can extract important information from curve data.
The HAPO study extended the Pedersen hypothesis about how maternal hyperglycemia affects the foetus [13] to the normal-glycaemic range, thereby giving rise to a comprehensive debate about the GDM diagnosis [11], [43]–[47]. In contrast to the WHO GDM criterion based on the fasting and 2-h value only [36], the new criteria suggested by the International Association of Diabetes and Pregnancy Study Group takes into consideration both the fasting, 1-h and 2-h OGTT values, with cut-off values based on risk estimates for adverse outcomes [47]. This implies that the new criteria indirectly address the dynamics in the curves. We have shown that modern statistical analysis can extract curve information reflecting glucose dynamics that is important for both maternal [20] and neonatal outcomes. This can contribute to a better understanding of the different stages in the development of unhealthy glucose metabolism, and to a more precise prediction of women at risk for maternal or foetal complications. Then, interventions targeted to modify glucose curves could be initiated before a GDM diagnosis is given, or treatment for it is necessary. Such interventions have been studied in pregnant and non-pregnant study samples [48]–[50]. Future studies should investigate whether such interventions also may affect pregnancy outcomes, and have positive long-term effects on maternal health.
In conclusion, the physiologically interpretable glucose curve characteristics extracted by FDA in the present analysis, and their statistically significant effects of on birth weight, neonatal percentage fat, and cord blood C-peptide, show that shape information inherent in entire glucose curves is important for several outcomes, and may contribute to the understanding of the metabolic changes during pregnancy. FDA techniques can also be used to capture important curve information from more frequently sampled glucose curves, such as the increasingly used continuous glucose monitoring devices.
Supporting Information
Table S1.
Correlations between glucose measurements and functional principal component scores.
https://doi.org/10.1371/journal.pone.0090798.s001
(PDF)
Appendix S1.
Multilevel functional data analysis (FDA), technical details.
https://doi.org/10.1371/journal.pone.0090798.s002
(PDF)
Acknowledgments
We gratefully acknowledge the help of each woman who participated and all the professional personnel at Oslo University Hospital Rikshospitalet who made this study possible.
Author Contributions
Conceived and designed the experiments: KFF JR EQ KG JB TH MBV. Analyzed the data: KFF. Wrote the paper: KFF JR EQ KG JB TH MBV.
References
- 1. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, et al. (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358: 1991–2002.
- 2. Ferrara A, Weiss NS, Hedderson MM, Quesenberry CP, Selby JV, et al. (2007) Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia. Diabetologia 50: 298–306.
- 3. Stotland NE, Caughey AB, Breed EM, Escobar GJ (2004) Risk factors and obstetric complications associated with macrosomia. Int J Gynaecol Obstet 87: 220–226.
- 4. McGowan CA, McAuliffe FM (2010) The influence of maternal glycaemia and dietary glycaemic index on pregnancy outcome in healthy mothers. Br J Nutr 104: 153–159.
- 5. Young BC, Ecker JL (2013) Fetal Macrosomia and Shoulder Dystocia in Women with Gestational Diabetes: Risks Amenable to Treatment? Curr Diab Rep 13: 12–18.
- 6. Scholl TO, Sowers M, Chen X, Lenders C (2001) Maternal glucose concentration influences fetal growth, gestation, and pregnancy complications. Am J Epidemiol 154: 514–520.
- 7. Ong KK, Diderholm B, Salzano G, Wingate D, Hughes IA, et al. (2008) Pregnancy insulin, glucose, and BMI contribute to birth outcomes in nondiabetic mothers. Diabetes Care 31: 2193–2197.
- 8. Jeffery AN, Voss LD, Metcalf BS, Wilkin TJ (2004) The impact of pregnancy weight and glucose on the metabolic health of mother and child in the south west of the UK. Midwifery 20: 281–289.
- 9. Parretti E, Mecacci F, Papini M, Cioni R, Carignani L, et al. (2001) Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care 24: 1319–1323.
- 10. Aparicio NJ, Joao MA, Cortelezzi M, Guz M, Sturgeon C, et al. (1998) Pregnant women with impaired tolerance to an oral glucose load in the afternoon: evidence suggesting that they behave metabolically as patients with gestational diabetes. Am J Obstet Gynecol 178: 1059–1066.
- 11. Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, et al. (2012) Gestational diabetes and pregnancy outcomes–a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth 12: 23.
- 12. Katon J, Williams MA, Reiber G, Miller E (2011) Antepartum A1C, maternal diabetes outcomes, and selected offspring outcomes: an epidemiological review. Paediatr Perinat Epidemiol 25: 265–276.
- 13.
Hod M, Jovanovic L, Di Renzo GC, de Leiva A, Langer O (2008) Textbook of diabetes and pregnancy. Andover, Hampshire: Taylor & Francis. 628 p.
- 14. Hadden DR, McLaughlin C (2009) Normal and abnormal maternal metabolism during pregnancy. Semin Fetal Neonatal Med 14: 66–71.
- 15. Mills JL, Jovanovic L, Knopp R, Aarons J, Conley M, et al. (1998) Physiological reduction in fasting plasma glucose concentration in the first trimester of normal pregnancy: The diabetes in early pregnancy study. Metabolism 47: 1140–1144.
- 16. Lind T, Billewic WZ, Brown G (1973) Serial Study of Changes Occurring in Oral Glucose-Tolerance Test During Pregnancy. J Obstet Gynaecol Br Commonw 80: 1033–1039.
- 17. Siegmund T, Rad NT, Ritterath C, Siebert G, Henrich W, et al. (2008) Longitudinal changes in the continuous glucose profile measured by the CGMS in healthy pregnant women and determination of cut-off values. Eur J Obstet Gynecol Reprod Biol 139: 46–52.
- 18. Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, et al. (1993) Carbohydrate-Metabolism During Pregnancy in Control Subjects and Women with Gestational Diabetes. Am J Physiol 264: E60–E67.
- 19. Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA (2011) Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged?. Diabetes Care 34: 1660–1668.
- 20. Frøslie KF, Røislien J, Qvigstad E, Godang K, Bollerslev J, et al. (2013) Shape information from glucose curves: Functional data analysis compared with traditional summary measures. BMC Med Res Methodol 13: 6.
- 21. Voldner N, Qvigstad E, Frøslie KF, Godang K, Henriksen T, et al. (2010) Increased risk of macrosomia among overweight women with high gestational rise in fasting glucose. J Matern Fetal Neonatal Med 23: 74–81.
- 22. Jovanovicpeterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, et al. (1991) Maternal Postprandial Glucose-Levels and Infant Birth-Weight - the Diabetes in Early-Pregnancy Study. Am J Obstet Gynecol 164: 103–111.
- 23.
Ramsay JO: Functional data analysis. Available: http://www.functionaldata.org. Accessed 15 October 2013.
- 24.
Ramsay JO, Silverman BW (2005) Functional Data Analysis. New York: Springer. 426 p.
- 25. Voldner N, Frøslie KF, Bø K, Haakstad L, Hoff C, et al. (2008) Modifiable determinants of fetal macrosomia: role of lifestyle-related factors. Acta Obstet Gynecol Scand 87: 423–429.
- 26. Di CZ, Crainiceanu CM, Caffo BS, Punjabi NM (2009) Multilevel Functional Principal Component Analysis. Ann Appl Stat 3: 458–488.
- 27. Crainiceanu C, Goldsmith AJ (2010) Bayesian Functional Data Analysis Using WinBUGS. J Stat Softw 32: 1–33.
- 28.
Voldner N (2010) Modifiable determinants of newborn macrosomia and birth complications. Dissertation for the Degree of PhD. Oslo: University of Oslo, Faculty of Medicine. 63 p.
- 29. Frøslie KF, Godang K, Bollerslev J, Henriksen T, Røislien J, et al. (2011) Correction of an unexpected increasing trend in glucose measurements during 7years recruitment to a cohort study. Clin Biochem 44: 1483–1486.
- 30. Godang K, Qvigstad E, Voldner N, Isaksen GA, Frøslie KF, et al. (2010) Assessing body composition in healthy newborn infants: reliability of dual-energy x-ray absorptiometry. J Clin Densitom 13: 151–160.
- 31. Godang K, Frøslie KF, Henriksen T, Isaksen GA, Voldner N, et al. (2013) Umbilical cord levels of sclerostin, placental weight, and birth weight are predictors of total bone mineral content in neonates. Eur J Endocrinol 168: 371–378.
- 32.
The R Foundation for Statistical Computing: R version 3.0.2 (2013-09-25). Available: http://www.r-project.org. Accessed 01 October 2013.
- 33. Trujillo-Arriaga HM, Roman-Ramos R (2008) Fitting and evaluating the glucose curve during a quasi continuous sampled oral glucose tolerance test. Comput Biol Med 38: 185–195.
- 34. Li J, Kuang Y, Mason CC (2006) Modeling the glucose-insulin regulatory system and ultradian insulin secretory oscillations with two explicit time delays. J Theor Biol 242: 722–735.
- 35. Sivan E, Chen X, Homko CJ, Reece EA, Boden G (1997) Longitudinal study of carbohydrate metabolism in healthy obese pregnant women. Diabetes Care 20: 1470–1475.
- 36. Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus - Provisional report of a WHO consultation. Diabet Med 15: 539–553.
- 37. Cousins L, Rigg L, Hollingsworth D, Brink G, Aurand J, et al. (1980) 24-Hour Excursion and Diurnal Rhythm of Glucose, Insulin, and C-Peptide in Normal-Pregnancy. Am J Obstet Gynecol 136: 483–488.
- 38.
World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hypergycemia. Report of a WHO/IDF consultation. Geneva, Switzerland: World Health Organization. 46 p.
- 39. HAPO Study Cooperative Research Group (2009) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 58: 453–459.
- 40. Beardsall K, Diderholm BMS, Dunger DB (2008) Insulin and carbohydrate metabolism. Best Pract Res Clin Endocrinol Metab 22: 41–55.
- 41. Chitayat L, Zisser H, Jovanovic L (2009) Continuous Glucose Monitoring During Pregnancy. Diabetes Technol Ther 11: S105–S111.
- 42. Buhling KJ, Winkel T, Wolf C, Kurzidim B, Mahmoudi M, et al. (2005) Optimal timing for postprandial glucose measurement in pregnant women with diabetes and a non-diabetic pregnant population evaluated by the Continuous Glucose Monitoring System (CGMS (R)). J Perinat Med 33: 125–131.
- 43. Coustan DR (2012) Point: the American Diabetes Association and the International Association of Diabetes and Pregnancy study groups recommendations for diagnosing gestational diabetes should be used worldwide. Clin Chem 58: 1094–1097.
- 44. Langer O, Umans JG, Miodovnik M (2013) The proposed GDM diagnostic criteria: a difference, to be a difference, must make a difference. J Matern Fetal Neonatal Med 26: 111–115.
- 45. Long H, Cundy T (2013) Establishing consensus in the diagnosis of gestational diabetes following HAPO: where do we stand? Curr Diab Rep 13: 43–50.
- 46. Coustan DR, Lowe LP, Metzger BE, Dyer AR (2010) The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 202: 654–656.
- 47. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33: 676–682.
- 48. Gumbiner B, Van CE, Beltz WF, Ditzler TM, Griver K, et al. (1996) Abnormalities of insulin pulsatility and glucose oscillations during meals in obese noninsulin-dependent diabetic patients: effects of weight reduction. J Clin Endocrinol Metab 81: 2061–2068.
- 49. Clapp JF III (1998) Effect of dietary carbohydrate on the glucose and insulin response to mixed caloric intake and exercise in both nonpregnant and pregnant women. Diabetes Care 21 (Suppl 2) B107–B112.
- 50. Dunstan DW, Kingwell BA, Larsen R, Healy GN, Cerin E, et al. (2012) Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care 35: 976–983.